FDA Drops Uganda Travel Screening After Ebola Outbreak Improves
On October 22, 2026, the FDA said blood establishments may stop asking donors about residency in or travel to Uganda. The change follows a significant improvement in the country’s Ebola situation and reflects how quickly donor eligibility policy can shift when a transfusion-transmitted infection retreats. Ebola disease remains a serious blood safety concern, but the current risk profile in Uganda no longer supports continued screening under the prior recommendation.
The agency tied the update to a clear epidemiologic marker: the last confirmed case of Ebola disease in Uganda was reported on June 21, 2026, and there are currently no active cases in the country. In practical terms, that means the temporary donor-history question added in response to the outbreak no longer needs to be part of the routine assessment for Uganda. Blood centers can remove that specific travel and residency screen while continuing to follow broader donor eligibility rules.
A single case count can change the workflow across an entire blood system.
Why the Donor Question Was Added in the First Place
Ebola disease is classified as a transfusion-transmitted infection under federal regulation, and that designation drives the caution around blood collection from people who may have had exposure. In June 2026, FDA issued guidance recommending that blood establishments update donor eligibility processes to assess and defer prospective donors at risk because of Ebola disease exposure. The same guidance explained that the agency would signal when blood establishments should revise donor history questionnaires in response to changing outbreak conditions.
That approach is designed to protect recipients before a pathogen can enter the blood supply. Because Ebola virus infection can be severe and because asymptomatic or pre-symptomatic exposure history may not be obvious at the point of donation, the donor questionnaire becomes a front-line safety tool. In outbreak settings, even a temporary geographic screen helps reduce the chance that infected or recently exposed individuals donate blood or blood components.
The June 29, 2026 safety communication was broader than Uganda alone. It described an outbreak of Bundibugyo virus disease in the Democratic Republic of the Congo and Uganda and directed blood establishments to update donor eligibility processes accordingly. The October 22 update narrows that response by removing Uganda from the list of countries requiring that specific assessment, while the rest of the outbreak monitoring framework remains in place.
What Blood Establishments Need to Change Now
The immediate operational change is straightforward: blood establishments may discontinue asking donors about residency in or travel to Uganda. That update affects donor history questionnaires, staff screening scripts, and the administrative logic used to defer prospective donors for Ebola risk tied to Uganda. It does not erase the need for vigilance around Ebola transmission in general, and it does not alter the agency’s broader expectation that blood collection systems stay aligned with current epidemiology.
FDA also said it will continue to monitor the Ebola disease outbreak in coordination with CDC and issue updated information as it becomes available. The agency specifically indicated that it will keep the list of countries requiring residency and travel history assessment under review. That means blood centers should treat this as a targeted policy revision, not a permanent relaxation of surveillance.
The update is grounded in a simple clinical principle: donor eligibility rules should track actual exposure risk, not historical concern alone. When a country’s active case burden falls to zero, the rationale for a special questionnaire item weakens. When transmission reappears, the screen can return quickly.
Surveillance Still Drives Blood Safety Policy
The FDA’s framework shows how tightly blood safety policy is linked to public health surveillance. The agency cited the improvement in Uganda’s situation as the basis for discontinuing the travel and residency question, and that decision was made alongside CDC monitoring rather than in isolation. For transfusion medicine, this kind of coordination matters because the blood supply depends on rapid translation of outbreak intelligence into front-line screening practices.
The underlying logic is conservative for good reason. Blood components bypass the body’s natural barriers, so pathogens that spread through body fluids can create consequences far beyond the individual donor. If a transfusion-transmitted infection is circulating in a region, donor screening becomes a risk-reduction measure that protects patients who may already be medically fragile, hospitalized, or dependent on repeated transfusion support.
Ebola disease is especially consequential because outbreak control and blood safety intersect so closely. A jurisdiction may move from heightened screening to routine screening only after the epidemiology improves enough to justify the change. Here, the last confirmed Ugandan case on June 21 and the absence of active cases provided the factual basis for that shift.
What Remains Under Watch
Even with the Uganda-specific screen lifted, the broader outbreak picture remains active enough to warrant continued attention. FDA said it will issue updated information as it becomes available, including the list of countries for which donor residency and travel history should be assessed. Blood establishments therefore still need a system that can respond to geographic changes without delay.
That flexibility is the real safeguard. A fixed questionnaire cannot protect blood recipients from a moving outbreak; only a system tied to current epidemiology can do that. The June guidance, the June 29 safety communication, and the October 22 update together form a staged response: identify the risk, restrict donation when necessary, and remove the restriction when the outbreak subsides.
For blood centers, the question now is not whether the policy should remain frozen. It is whether screening protocols can continue to track the next change with the same speed FDA used here. The agency’s next communication will determine whether the list of countries expands, contracts, or remains unchanged as Ebola surveillance continues.